CoV-2 S1 (319-529)
HEK293 Cells.
Severe acute respiratory syndrome coronavirus 2, COVID-19, COVID-19 virus, COVID19, HCoV-19, Human coronavirus 2019, SARS-2, SARS-CoV2, SARS2, Wuhan coronavirus, Wuhan seafood market pneumonia virus, SARS-CoV-2 SP RBD, 2019-nCoV SP RBD, 2019-nCoV, 2019-nCoV; Spike RBD Protein.
Greater than 95.0% as determined by SDS-PAGE.
Description
The recombinant Coronavirus 2019-nCoV Spike Glycoprotein-S1 Receptor Binding Domain containing a total of 221 amino acids (319-529) and having a calculated Mw of 24.9 kDa.
CoV-2 S1 (319-529) is fused to a 10 amino acid His-tag at C-terminus,and is purified by proprietary chromatographic techniques.
Product Specs
Severe acute respiratory syndrome coronavirus 2, COVID-19, COVID-19 virus, COVID19, HCoV-19, Human coronavirus 2019, SARS-2, SARS-CoV2, SARS2, Wuhan coronavirus, Wuhan seafood market pneumonia virus, SARS-CoV-2 SP RBD, 2019-nCoV SP RBD, 2019-nCoV, 2019-nCoV; Spike RBD Protein.
HEK293 Cells.
DGSMRVQPTE SIVRFPNITN LCPFGEVFNA TRFASVYAWN RKRISNCVAD YSVLYNSASF STFKCYGVSP TKLNDLCFTN VYADSFVIRG DEVRQIAPGQ TGKIADYNYK LPDDFTGCVI AWNSNNLDSK VGGNYNYLYR LFRKSNLKPF ERDISTEIYQ AGSTPCNGVE GFNCYFPLQS YGFQPTNGVG YQPYRVVVLS FELLHAPATV CGPKKHHHHH H
Product Science Overview
The Coronavirus 2019-nCoV, also known as SARS-CoV-2, is the virus responsible for the COVID-19 pandemic. One of the critical components of this virus is the spike (S) glycoprotein, which plays a crucial role in the virus’s ability to infect host cells. The spike glycoprotein is a large, trimeric protein that protrudes from the surface of the virus and is essential for virus attachment, fusion, and entry into the host cell .
The spike glycoprotein is composed of two subunits: S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which is responsible for binding to the host cell receptor, angiotensin-converting enzyme 2 (ACE2). The S2 subunit mediates the fusion of the viral and host cell membranes .
The RBD within the S1 subunit spans amino acids 319 to 529 and is critical for the virus’s ability to recognize and bind to ACE2. This binding is the first step in the viral entry process, making the RBD a key target for neutralizing antibodies and vaccine development .
The recombinant form of the RBD (319-529 a.a.) is produced using recombinant DNA technology. This involves inserting the gene encoding the RBD into an expression system, such as bacteria, yeast, or mammalian cells, to produce the protein in large quantities. The recombinant RBD can then be purified and used for various applications, including vaccine development, diagnostic assays, and therapeutic interventions .
- Vaccine Development: The RBD is a major target for vaccine development because it elicits a strong immune response. Vaccines based on the RBD can induce the production of neutralizing antibodies that block the virus from binding to ACE2, thereby preventing infection .
- Diagnostic Assays: Recombinant RBD can be used in serological assays to detect antibodies against SARS-CoV-2 in patient samples. These assays are essential for diagnosing past infections and assessing the immune response to vaccination .
- Therapeutic Interventions: The RBD can be used to develop therapeutic antibodies that specifically target and neutralize the virus. These antibodies can be used to treat COVID-19 patients and provide passive immunity to high-risk individuals .
